Shaanxi BLOOM Tech Co., Ltd. is one of the most experienced manufacturers and suppliers of linaclotide peptide in China. Welcome to wholesale bulk high quality linaclotide peptide for sale here from our factory. Good service and reasonable price are available.
Linaclotide peptide is a synthetic 14‑amino acid molecule with the molecular formula C₅₉H₇₉N₁₅O₂₁S₆ and CAS number 851199‑59‑2. Its mechanism is centered on the activation of guanylate cyclase‑C (GC‑C) receptors in the intestinal epithelium. Upon binding, it triggers localized signaling that enhances fluid secretion into the gut lumen, accelerates intestinal transit, and participates in the regulation of sensory pathways. As a peptide‑based GC‑C agonist, it acts specifically within the intestinal tract without systemic absorption, contributing to its targeted and well‑tolerated activity profile.
Our Products Form
Linaclotide COA
Therapeutic use of Linaclotide
The clinical utility of linaclotide peptide is defined by its targeted, local action within the gastrointestinal tract, addressing disorders rooted in impaired secretion, slowed motility, and heightened visceral sensitivity. Its value lies not only in symptom relief but also in improving overall bowel function and patient quality of life through a well-characterized dual mechanism. The primary areas of established and prospective application are outlined below.
Potential in Broader Gastrointestinal Dysfunction
Ongoing clinical investigation continues to explore the role of this drug in other conditions characterized by altered gut secretion, transit, or sensitivity. Research is examining its potential utility in scenarios such as opioid-induced constipation, postoperative ileus, and certain refractory motility disorders. While these applications are not yet part of standard labeling, they highlight the peptide's versatile pharmacodynamic profile. The underlying mechanism-localized enhancement of fluid secretion and dampening of neural hypersensitivity-may hold promise for managing a spectrum of functional GI disturbances where these pathways are implicated.
Convenient medication:
This is a daily advantage considered for you. It adopts a once daily dosing regimen, with a simple administration method (usually taken on an empty stomach), which is easy to integrate into the patient's daily routine and helps improve medication compliance in the treatment of chronic diseases, ensuring stable efficacy.
Structural and Chemical Profile
Physicochemical Properties:
peptide Sequence:
Linaclotide comprises 14 amino acids linked by peptide bonds.
Multiple disulfide bridges between cysteine residues ensure a stable structure essential for receptor binding and activity.
Discovery and Development History
The development of linaclotide peptide stems from targeted research into gastrointestinal physiology and peptide therapeutics. Below are key phases in its scientific evolution, encompassing the identification of the GC-C pathway as a therapeutic target, the rational design of the peptide structure, and its formulation into a viable clinical candidate.
1. Early Research on Guanylate Cyclase-C Signaling
Initial studies identified the guanylate cyclase-C (GC-C) receptor as a key regulator of intestinal secretion. Researchers recognized that synthetic analogs of natural peptides could potentially treat motility disorders by activating this pathway. This insight provided the foundational rationale for developing a stable, non-degradable peptide agonist targeting the gastrointestinal tract.
2. Peptide Design and Stabilization
It was developed as a 14‑amino acid peptide stabilized by multiple disulfide bonds, which improve both its structural stability and receptor-binding affinity. The peptide's architecture is specifically tailored to withstand degradation in the gastrointestinal environment while preserving its localized intestinal activity. This design ensures high selectivity for the GC‑C receptor and reduces vulnerability to enzymatic digestion during transit through the digestive tract.
3. From Discovery to Development Candidate
Preclinical studies verified that it effectively promotes fluid secretion and lowers visceral sensitivity without entering systemic circulation. Its development into a lyophilized powder combined with an enteric‑protected delivery system supported its progression as a clinically viable, gut‑targeted agent. Through advanced formulation strategies, both stability and bioavailability were further improved, facilitating its successful advancement into a practical therapeutic alternative.
Functional Effects in the Intestinal Environment
Activation of GC‑C receptors elevates intracellular cGMP levels, leading to the opening of CFTR and other anion channels located on the epithelial surface. The consequent efflux of chloride and bicarbonate ions establishes an osmotic gradient that drives water secretion into the intestinal lumen. This mechanism not only helps soften intestinal contents but also gently distends the gut wall, which in turn promotes peristaltic movement and contributes to the maintenance of regular intestinal transit.
2.Reduction of Visceral Sensitivity
Beyond its secretagogue action, linaclotide peptide modulates gut‑brain signaling pathways through a sophisticated neuro‑regulatory mechanism. Elevated cGMP in the submucosa decreases the excitability of afferent sensory nerves, effectively reducing their sensitivity to mechanical stimuli. By raising the threshold for mechanosensory activation, the peptide helps attenuate abnormal responses to normal degrees of intestinal distension, thereby diminishing the transmission of exaggerated or discomfort-associated signals to the central nervous system. This mechanism contributes to an overall reduction in sensory over‑activity within the gut, supporting the normalization of visceral perception. The dual effect of enhancing secretion while calming sensory hyperactivity positions this drugs as a comprehensive modulator of both motility and discomfort-related signaling in functional gastrointestinal contexts.
By accelerating transit and reducing stasis, it helps limit the accumulation of metabolic waste and potential irritants in the intestine. This may support a healthier mucosal environment and contribute to the normalization of local microbial communities. Although not a direct anti‑inflammatory agent, the peptide's ability to improve luminal clearance may indirectly lower local inflammatory triggers.
Pharmaceutical Development Considerations
Formulation Design
Given its peptide nature, formulation strategies focus on maintaining stability, ensuring adequate dissolution, and protecting the molecule from degradation in the upper gastrointestinal tract. Lyophilization is frequently used to produce a stable solid intermediate. The final product is designed to release the peptide in the proximal small intestine, where GC‑C receptors are abundantly expressed.
Stability and Storage
This drug is typically stored as a lyophilized solid under controlled conditions: sealed, protected from light, and kept in a cool, dry environment (often at 2–8 °C). These measures prevent oxidation, hydrolysis, and aggregation, thereby preserving its conformational integrity and biological activity over the shelf life.
Manufacturing
Industrial production relies on advanced solid‑phase peptide synthesis, followed by purification steps such as reverse‑phase high‑performance liquid chromatography (RP‑HPLC). Rigorous quality control ensures batch‑to‑batch consistency in purity, potency, and disulfide bridge formation.
Research and Development Outlook
Expanding Functional Applications
Ongoing research explores the potential utility of it in a broader range of gastrointestinal functional disorders. Studies are investigating its effects in models characterized by reduced motility, altered secretion, or heightened visceral sensitivity. While these investigations remain exploratory, they highlight the peptide's versatile mechanism that may address multiple pathophysiological facets of gut dysfunction.
Innovation in Delivery and Presentation
Future development may focus on novel delivery systems that further enhance the peptide's stability, bioavailability, or release profile. Approaches such as enteric‑coated microparticles, sustained‑release matrices, or combination formulations are under consideration to optimize performance and user convenience.
Global Market Dynamics
Growing recognition of gastrointestinal functional disorders, together with advances in peptide therapeutics, supports continued interest in it. Efforts to adapt the product to diverse regulatory and healthcare environments are expected to facilitate wider availability. Strategic partnerships and local manufacturing initiatives could play a role in extending access to new regions.
Collectively, these three strategic pillars-expanding therapeutic indications, advancing delivery technology, and navigating global market landscapes-are poised to unlock the full potential of linaclotide peptide. By leveraging its unique mechanism of action and refining its clinical and commercial viability, the R&D roadmap not only aims to address unmet medical needs in gastrointestinal care but also to establish the peptide as a cornerstone therapy in the global peptide therapeutics market. With sustained investment in research, cross-functional collaboration, and regulatory agility, this peptide is well-positioned to deliver meaningful benefits to patients worldwide while driving long-term growth and innovation in the field.
Frequently Asked Questions
What is Linaclotide?
Linaclotide peptide is a synthetically produced 14‑amino acid compound that acts as a guanylate cyclase‑C (GC‑C) receptor agonist. It is designed to act locally within the intestinal tract to promote fluid secretion and modulate sensory signaling.
How does this drug differ from other agents?
Unlike systemically absorbed drugs, linaclotide peptide operates exclusively within the gut lumen and epithelium, exerting its effects locally without entering the bloodstream. This site-specific activity ensures a targeted therapeutic action while minimizing the risk of systemic side effects. Its dual mechanism-promoting secretion while reducing sensory over-activity-provides a multifaceted approach to managing gastrointestinal function, addressing both the physical and sensory aspects of functional bowel disorders. This combination enables a more holistic regulation of intestinal motility and comfort, making it uniquely positioned among gastrointestinal therapeutics to simultaneously improve transit and alleviate discomfort-related symptoms.
What are the stability considerations for linaclotide?
The peptide is sensitive to extreme pH, heat, and oxidation. It is commonly stabilized as a lyophilized powder and stored under cool, dry, light‑protected conditions to maintain its conformational and functional integrity.
Can linaclotide peptide be manufactured at scale?
Yes, using modern solid‑phase peptide synthesis (SPPS) combined with high‑resolution purification techniques, linaclotide peptide can be produced consistently at commercial scale with high purity and correct disulfide bonding.
Hot Tags: linaclotide peptide, suppliers, manufacturers, factory, wholesale, buy, price, bulk, for sale, Bremelanotide Powder CAS 189691 06 3, dermorphin in humans, dermorphin peptide, Kisspeptin powder, Melanotan ii powder, Tesamorelin CAS 218949 48 5